NASDAQ · TWST
Twist Bioscience Corporation
$173.45$0.00 (0.0%)
Twist Bioscience Corporation’s quoted price sits in the upper half of its reported 52-week range, 21.06% below the high.
Loading market information…
NYSE · GRDN · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Guardian Pharmacy Services, Inc.’s quoted price sits in the upper half of its reported 52-week range, 16.3% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Guardian Pharmacy Services, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of $0.31. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Guardian Pharmacy Services, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Guardian Pharmacy Services, Inc. operates as a pharmaceutical service provider, delivering an extensive array of tech-driven solutions. These services are specifically crafted to enhance the care of residents within long-term health care facilities (LTCFs) across the United States. The company specializes in offering personalized clinical assistance, efficient drug distribution, and comprehensive administrative support. These provisions are particularly beneficial for individuals in less acute long-term care environments, such as assisted living communities, behavioral health centers, and group homes. To bolster its operations, the company offers Guardian Compass, a platform that generates insightful dashboards from its extensive data warehouse. This tool enables its network of local pharmacies to effectively strategize, monitor performance, and refine their business processes. Furthermore, Guardian Pharmacy Services develops dedicated GuardianShield Programs for LTCFs. The company was established in 2003 and is based in Atlanta, Georgia.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:52 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 12, 2025 | $0.21-4.55% vs estimate | $329.31M-0.04% vs estimate |
|---|
| Q4 2024 | Mar 26, 2025 | $0.24+14.29% vs estimate | $338.57M+4.79% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | -$2.00-1,152.63% vs estimate | $314.39M+3.72% vs estimate |
|---|
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $51.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$173.45$0.00 (0.0%)
Twist Bioscience Corporation’s quoted price sits in the upper half of its reported 52-week range, 21.06% below the high.
$81.55-$2.07 (-2.48%)
10x Genomics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 20.68% below the high.
$38.91-$1.58 (-3.9%)
Edgewise Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 19.79% below the high.
$212.16+$0.37 (+0.17%)
National HealthCare Corporation’s quoted price sits in the upper half of its reported 52-week range, 14.52% below the high.
$29.18+$0.27 (+0.93%)
Pediatrix Medical Group, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.48% below the high.
$15.67+$2.28 (+17.03%)
Mesoblast Limited’s quoted price sits in the lower half of its reported 52-week range, 27.12% below the high.
$4.77+$0.18 (+3.92%)
Nuvation Bio Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.08% below the high.
$20.30+$0.10 (+0.5%)
PROCEPT BioRobotics Corporation’s quoted price sits in the lower half of its reported 52-week range, 46.73% below the high.
